...
首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Design, synthesis and evaluation of novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety as antiangiogenic agents.
【24h】

Design, synthesis and evaluation of novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety as antiangiogenic agents.

机译:设计,合成和评估新的苯并咪唑,苯并噻唑和苯并呋喃,并结合吡唑部分作为抗血管生成剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety have been synthesized and screened for their antiangogenic activities, by testing their ability to inhibit human umbilical vein endothelial cell (HUVEC) proliferation, cord formation and migration in response to chemoattractant. 3 compounds 19, 23 and 26 showed antiangiogenic activities at non-cytotoxic concentrations. Compound 19 was the most active with chemotaxis activity data nearly comparable to that of the positive control, TNP-470. Compound 42 showed a significant cytotoxic effect on the tested cancer cell lines and less antiangiogenesis activity compared to compounds 19, 23 and 26. All the tested compounds, in contrary to TNP-470, interfered with the migratory function of HUVECs in response to vascular endothelial growth factor rather than the endothelial cells proliferation or cord formation. Moreover, a docked pose of compounds 19 and 26 was obtained bound to kinase insert domain receptor using Molecular Operating Environment module.
机译:合成了新的并有吡唑部分的苯并咪唑,苯并噻唑和苯并呋喃,并通过测试其抑制人脐静脉内皮细胞(HUVEC)增殖,响应化学趋化作用而形成的脐带形成和迁移的能力,筛选了它们的抗血管生成活性。 3种化合物19、23和26在非细胞毒性浓度下显示出抗血管生成活性。化合物19最活跃,趋化活性数据几乎与阳性对照TNP-470相当。与化合物19、23和26相比,化合物42对受试癌细胞系显示出显着的细胞毒性作用,抗血管生成活性较弱。与TNP-470相反,所有受试化合物均干扰HUVEC响应血管内皮的迁移功能生长因子而不是内皮细胞增殖或索形成。此外,使用分子操作环境模块获得了与激酶插入结构域受体结合的化合物19和26的对接姿势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号